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Youth in transition: Study protocol of a
prospective cohort study into the long-
term course of addiction, mental health
problems and social functioning in youth
entering addiction treatment
Christina Moska1,2, Anna E. Goudriaan3,4* , Peter Blanken1, Dike van de Mheen5, Renske Spijkerman1,
Arnt Schellekens6,7, Jannet de Jonge8, Floris Bary9, Wilma Vollebergh10 and Vincent Hendriks1,2
Abstract
Background: Substance use disorders (SUDs) are prevalent in the general population, tend to follow a chronic
course, are associated with many individual and social problems, and often have their onset in adolescence.
However, the knowledge base from prospective population surveys and treatment-outcome studies on the course
of SUD in adolescents is limited at best. The present study aims to fill this gap and focuses on a subgroup that is
particularly at risk for chronicity: adolescents in addiction treatment. We will investigate the rate of persistent SUD
and its predictors longitudinally from adolescence to young adulthood among youth with DSM-5 SUD from the
start of their addiction treatment to 2 and 4 years following treatment-entry. In addition to SUD, we will investigate
the course of comorbid mental disorders, social functioning, and quality of life and their association with SUD over
time.
Methods/design: In a naturalistic, multi-center prospective cohort design, we will include youths (n = 420), who
consecutively enter addiction treatment at ten participating organizations in the Netherlands. Inclusion is
prestratified by treatment organization, to ensure a nationally representative sample. Eligible youths are 16 to 22
years old and seek help for a primary DSM-5 cannabis, alcohol, cocaine or amphetamine use disorder. Assessments
focus on lifetime and current substance use and SUD, non-SUD mental disorders, family history, life events, social
functioning, treatment history, quality of life, chronic stress indicators (hair cortisol) and neuropsychological tests
(computerized executive function tasks) and are conducted at baseline, end of treatment, and 2 and 4 years post-
baseline. Baseline data and treatment data (type, intensity, duration) will be used to predict outcome – persistence
of or desistance from SUD.
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Discussion: There are remarkably few prospective studies worldwide that investigated the course of SUD in
adolescents in addiction treatment for longer than 1 year. We are confident that the Youth in Transition study will
further our understanding of determinants and consequences of persistent SUD among high-risk adolescents
during the critical transition from adolescence to young adulthood.
Trial registration: The Netherlands National Trial Register Trial NL7928. Date of registration January 17, 2019.
Keywords: Adolescents, Youth addiction treatment, Substance use disorder, Long-term course of SUD, Prospective
cohort study
Background
Substance use disorders (SUDs) are prevalent in the gen-
eral adult population [1], tend to follow a chronic or
chronic-intermittent course, are associated with many
individual and social problems, and – as most mental
disorders – often have their onset in adolescence [2].
Hence, the course of SUD among adolescents and young
adults should be high on our research agenda. Neverthe-
less, the literature regarding the development, persist-
ence or desistance and treatment of SUD in youth is
sparse, and research in this area lags considerably behind
that of research in adult SUD.
When studying substance use ‘trajectories’ several
transitions can be distinguished. The first series of tran-
sitions cover the initiation of substance use, and the
transition from first use to regular or frequent use, and
from frequent use to disordered use. The subsequent
transition pertains to the persistence or desistance of
SUD. In the present study we examine the last transition
– the persistence of or desistance from SUD in the
period from late adolescence (i.e., 16 to 22 yrs) to early
adulthood (20 to 26 yrs) – among youth in addiction
treatment.
Various prospective studies have traced the progres-
sion from first substance use through frequent con-
sumption to the onset of SUD in community samples of
adolescents, with most studies pertaining to cannabis,
the most commonly used illicit drug worldwide [3–7].
Most substance use in adolescents remains experimental,
irregular or modest. However, it tends to become more
frequent, intensive and long-lasting when the use of sub-
stances is part of multiple problem behavior including
comorbidity with mental health problems, social dys-
function, and delinquency [7–9].
Much less is known about what happens next: the
course of SUD during the critical transition period from
adolescence to adulthood. Based on Moffitt’s taxonomy
of antisocial behavior [10, 11], the literature distin-
guishes between adolescent-limited and life-course-
persistent trajectories of substance use and SUD, but few
prospective population studies have in fact addressed
this issue, and virtually all studies were conducted in the
United States, Australia and New Zealand [12–16]. For
example, Meier et al. (2015) investigated the develop-
ment of persistent substance dependence on alcohol,
nicotine, cannabis or hard drugs from adolescence to
adulthood up to 38 years in the Dunedin birth cohort in
New Zealand, and found a persistence rate of substance
dependence of 19% when including nicotine depend-
ence, and of 9% when excluding nicotine dependence
from the outcome. In addition, they found a specific set
of childhood and adolescent risk factors, including fam-
ily history of SUD, childhood psychopathology, and
childhood socioeconomic status, to be strongly associ-
ated with persistent substance dependence in adulthood.
Only a few European population studies investigated the
course of SUD from adolescence to young adulthood,
but these focused on cannabis only [17, 18].
The present study focuses on a population that is par-
ticularly at risk for chronicity: adolescents in addiction
treatment. Although research on treatment outcome of
adolescents with SUD has expanded in the past decade
[19], there are remarkably few studies that investigated
the course of SUD in adolescents following addiction
treatment prospectively for longer than 1 year. We
found only three large-scale (N > 300) studies that did so
[20–22]. Results from these – all US-based – studies
suggest that, despite overall treatment benefit, roughly
15 to 30% of treated adolescents show a pattern of per-
sistent SUD/dependence or even deterioration during
the 3 to 6 years post-treatment.
To conclude, the available data from prospective
population surveys and treatment-outcome studies on
the course of SUD in adolescents are limited at best. Re-
mission, continuation and progression rates are largely
unknown, as are the risk and protective factors involved.
While nearly 6000 youth aged 22 years or younger enter
treatment for SUD annually in the Netherlands [23], we
have virtually no information as to how these youth will
fare moving from adolescence to early adulthood. The
present study aims to fill these gaps by addressing the
study objectives outlined below.
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Study objectives
In this study, we will investigate the rate of persistent
SUD and its predictors longitudinally from adolescence
to young adulthood in a representative treatment sample
of youth with DSM-5 SUD from the start of their addic-
tion treatment to 2 and 4 years following treatment-
entry. In addition to SUD, we will investigate the course
of comorbid mental disorders and social functioning,
and their relation with SUD over time.
Our primary study questions are:
(1) What is the persistence rate of DSM-5 moderate to
severe SUD from adolescence to young adulthood
among youth in the two and four years following
entry in addiction treatment?
(2) What is the prognostic value of a general
population-based set of predictors of persistent
SUD – based on the Dutch Tracking Adolescents’
Individual Lives Survey (TRAILS) study – from
adolescence to young adulthood for predicting per-
sistent DSM-5 moderate to severe SUD among
youth in addiction treatment?
(3) Can we optimize the accuracy of predicting
persistent DSM-5 moderate to severe SUD among
youth in addiction treatment by extending or modi-
fying the general population-based set of predictors
with baseline indicators from our addiction treat-
ment sample?
(4) Which longitudinal treatment outcome trajectories
can be identified from adolescence to young
adulthood pertaining to substance use and SUD,
comorbid mental health problems, and social
functioning among youth in addiction treatment?
(5) Which treatment interventions – in terms of type,
intensity and duration – are associated with
favorable or unfavorable long-term outcomes, in
terms of substance use and SUD, mental health




Our study is designed as a naturalistic, multi-center pro-
spective cohort study among youth seeking help in ad-
diction treatment to investigate the study objectives
mentioned above.
We will recruit youth aged 16 to 22 years (N = 420)
who enter addiction treatment at ten participating treat-
ment organizations from a total of 13 organizations in
the Netherlands. Participants will be assessed on a range
of measures related to substance use and SUD, comor-
bid mental health problems and social functioning at
treatment-entry (baseline), end of treatment, and 2 and
4 years post-baseline. Study-inflow of participants
consists of consecutive admissions, and will be prestrati-
fied by treatment organization to ensure a nationally
representative sample. Treatment consists of treatment
as usual, as provided by the participating addiction care
organizations, to maximize generalizability of the study
findings to everyday clinical practice. Analyses will be
conducted following an intention-to-treat approach.
This study was funded by The Netherlands
Organization for Health Research and Development
(60–63,600–98-317) and was approved by the Medical
Ethical Board of the Leiden University Medical Center
(NL65903.058.18; file number P18.175). Trial registra-
tion: NL7928.
Participants and setting
Based on national treatment registration data [23], a
total of 5769 youth up to age 22 years applied for addic-
tion treatment in the Netherlands in 2015. From these,
the far majority (N = 5151; 89%) were 16 to 22 years old,
and most sought help for a primary cannabis- (53%), al-
cohol- (17%) or stimulant- (11%, cocaine or amphet-
amine) related problem. Hence, 81% (N = 4169) of total
treatment demand among youth aged 16–22 years con-
cerns cannabis, alcohol, cocaine and/or amphetamines,
with other substances (e.g., opiates, ecstasy, GHB, and
benzodiazepines) each representing less than 2% of
treatment demand. Limiting our inclusion to youth aged
16–22 years, with the primary substances mentioned
above, and using a sampling fraction of 10%, 420 youth
will be included in our study (see Fig. 1).
Inclusion criteria are: age 16 to 22 years; primary SUD
pertains to cannabis, alcohol, cocaine or amphetamines;
willingness to participate in the study (oral and written
informed consent). Exclusion criteria are: referral for
diagnostic evaluation only; insufficient comprehension of
basic Dutch language. The ten participating organiza-
tions include specialized addiction treatments and inte-
grated mental health and addiction treatments, with
treatment covered by the health insurance system. Re-
cruitment of study participants takes place at 41 treat-
ment locations situated throughout the Netherlands.
Treatment
Treatment consists of the usual treatment-offer provided
by the addiction care organizations to maximize eco-
logical validity of the study outcomes. We will document
the type of treatment received for SUD, which in the
Netherlands mostly consists of integrated cognitive be-
havioral therapy plus motivational interviewing (CBT +
MI), community reinforcement approach (CRA), family
therapy, and CBT-based e-health interventions. In
addition, we will document – psychosocial and/or
pharmacological – treatment for comorbid mental
health problems as well as intensity (inpatient;
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outpatient) and actual duration (retention) of treatment,
and type of treatment termination (premature/planned).
Assessments
Study assessments take place at study-entry (baseline),
end of treatment, and 2 and 4 years post-baseline, and
will be conducted by trained, academic level, research
assistants, who are independent from the treatment-
staff. Youth who apply for treatment at the participating
treatment centers will be approached by treatment-staff
with the request to participate in the study. Following
screening for eligibility, participants are asked to provide
informed consent, after which the baseline assessment
and subsequent two- and four-years follow-up will be
conducted.
For the purpose of the present study, we developed
the Youth in Transition Questionnaire (YIT-Q [24]),
which contains both widely used instruments like the
Depression, Anxiety and Stress Scale (DASS-21 [25])
and the World Health Organization Disability Assess-
ment Schedule (WHODAS-2.0 [26]) as well as domains
with item-sets that were developed by our research
group (see Table 1). Both the DASS-21 and the
WHODAS-2.0 have shown a stable factor structure, and
their scales have excellent internal consistency reliability
and good convergent en discriminant validity (e.g., [27,
28]).
At baseline, we collect sociodemographic information
and administer the substance use section of the Mea-
surements in the Addictions for Triage and Evaluation –
Youth version (MATE-Y [29]), which is the standard in-
take instrument in most youth addiction treatment orga-
nizations in the Netherlands. Both lifetime (onset,
duration) and past-month (days of use) substance use
data are collected, and the criteria of the fifth edition of
the Diagnostic and Statistical Manual of Mental Disor-
ders (DSM-5 [30]) are administered to obtain a lifetime
and past-year diagnosis of SUD for the primary and – if
present – secondary substance for which the youths seek
help. To assess the presence of comorbid non-SUD
mental disorders, we developed a structured DSM-5
diagnostic interview which covers ten of the most com-
mon disorders: depression; panic disorder; agoraphobia;
social phobia; post-traumatic stress disorder; attention-
Fig. 1 Flowchart of the Youth in Transition study
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deficit/hyperactivity disorder; conduct disorder; anorexia
nervosa and bulimia nervosa; generalized anxiety dis-
order. For each disorder, the main diagnostic criteria are
used as screening questions, and only if these main cri-
teria are met in a period that the person was not intoxi-
cated and did not experience alcohol or drug withdrawal
symptoms – hence, do not reflect a substance-induced
disorder only – the full section of that disorder is
administered. In addition to DSM-5 classification, the
DASS-21 (depression, anxiety, stress), Prodromal Ques-
tionnaire (PQ-16 [31]) (subclinical psychotic symptoms),
Substance Use Risk Profile Scale (SURPS [32]) (personal-
ity risk for substance abuse) and Screener for
Intelligence and Learning disability (SCIL [33]) are ad-
ministered to obtain dimensional measures of mental
health, and the WHODAS-2.0 is used to assess general
Table 1 Assessment domains and instruments







• Age; sex; cultural background/identity YIT-Q X
• Family educational level and socioeconomic status YIT-Q X
Substance use
• Lifetime and recent substance use MATE-Y X X X
• DSM-5 substance use disorder (SUD); age of onset MATE-Y X X X
Non-SUD mental disorders
• DSM-5 lifetime and past-year mental disorders; age of onset Structured DSM-5 interview X X X
• Dimensional measures of mental health problems, including
depression, anxiety, stress; prodromal psychotic symptoms;
personality risk for substance abuse; intellectual disability
DASS-21; PQ-16; X X X
SURPS; SCIL X
• Suicidal ideation/attempts MINI X X
Family history/environment
• History of SUD (parents; grandparents; siblings) YIT-Q X
• History of non-SUD mental disorders; criminality,




• Traumatic life events Structured DSM-5 interview X X X
• Turning points with major impact on addiction course YIT-Q X X
Social functioning
• Youth’s functioning in the areas of: education; employment;
living arrangements; social relationships/support; delinquency
YIT-Q X X X
• General functioning, disability and quality of life WHODAS-2.0 X X X
Treatment history
• Number/types of earlier addiction and mental health
treatments
YIT-Q X X X
• Intention/motivation for current treatment YIT-Q X
Endophenotype and biomarker
• Behavioral measures of impulsivity (computerized tasks) Risky Gains task, VBDM, Self-
Ordered Pointing task
X X X
• Biomarkers of chronic stress: hair cortisol and testosterone Hair sample analysis X X X
Index treatment characteristics
• Type, intensity, duration of current treatment received and initial
treatment responsea
X
DASS-21 Depression, Anxiety and Stress Scale, MATE-Y Measurements in the Addictions for Triage and Evaluation – Youth version, PQ-16 Prodromal Questionnaire
– 16 item version, SCIL Screener for Intelligence and Learning disability, SURPS Substance Use Risk Profile Scale, VBDM Valued-based decision-making battery,
WHODAS-2.0 World Health Organization Disability Assessment Schedule, YIT-Q Youth In Transition Questionnaire
aNote: All information at the end of treatment assessment will be obtained from the responsible clinician
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functioning, disability and quality of life. The PQ-16 was
found to accurately identify ultra high risk (UHR) and
full psychosis, with area under the curve (AUC) values
ranging from 0.71 to 0.95 [34], and the SURPS showed
adequate to high internal consistency (Cronbach’s
alpha = 0.61–0.86), a stable factor structure that reflects
the four scales of the instrument, and good test-retest
reliability, with intra-class correlation coefficients (ICC)
ranging from 0.68 to 0.88 [35]. The SCIL has shown ex-
cellent test-retest reliability (Pearson’s r = 0.92) and good
predictive validity for detecting mild or borderline intel-
lectual disabilities in both adults (AUC = 0.93) and
youths (AUC = 0.91) [33].
The YIT-Q assessment domains pertaining to family
history/environment, social functioning and treatment
history/motivation all contain structured questions
which inform about the youth’s self-reported perception
of his/her own functioning or problems in these areas,
or – in the case of family history – his/her perception of
his family members’ functioning/problems (see Table 1).
Questions pertaining to suicidal ideation/attempts were
derived from the Mini International Neuropsychiatric
Interview (MINI, version 5.0.0 [36]). For assessing family
history of SUD, non-SUD mental disorders and crimin-
ality we used the Family History Method (FHM [37]) as
described by Schuckit et al. (2020). Given that the FHM
tends to underestimate family diagnosis, we aimed to in-
crease its sensitivity by asking the youth whether his/her
(grand)parent(s) or sibling(s) had ever received treat-
ment for alcohol, drug or mental health problems, or
whether they had ever been incarcerated. We derived
and adapted a set of questions about family history of
violence, abuse and neglect towards the youth from the
International Society for the Prevention of Child Abuse
& Neglect (ISPCAN) Child Abuse Screening Tools
(ICAST), version for young adults (ICAST-R [38]). For
assessing important ‘turning points’ that had a major im-
pact on the course of the youth’s substance use career,
we will use a qualitative approach with open-ended
questions [39]. Questions on the youth’s social function-
ing, including employment, living arrangements, social
support and delinquency were derived and adapted from
item-sets in the Substance Use Recovery Evaluator
(SURE [40]) and the Treatment Outcomes Profile (TOP
[41]). Both instruments are widely used and validated,
and are included in the recent International Consortium
for Health Outcomes Measurement (ICHOM [42])
standard set for addiction. For example, the five sub-
scales of the SURE showed good internal consistency
(alpha = 0.68–0.87), and reflect a stable factor structure
of the instrument [40]. In addition, all items of the TOP
in the areas of employment, living arrangements and de-
linquency showed ‘substantial’ or ‘good’ inter-rater reli-
ability, with Cohen’s kappa> 0.61, and ICC > 0.75,
respectively [41]. We limited our assessment of
intention/motivation for treatment to a single-item
question pertaining to the youth’s self-reported primary
goal of treatment – total abstinence or strong/small/no
reduction of substance use.
In addition to the self-reported measures described
above, we administer several computerized tasks pertain-
ing to impulsive or risky choice and value-based
decision-making (VBDM). Specifically, we include a
delay discounting task, in which four versions are ad-
ministered: a) delay discounting; b) probability discount-
ing of gains; c) probability discounting of losses; d)
mixed gambles. The task is administered using
MATLAB software; further details on task description
can be found in [43]. In addition, a computerized self-
ordered pointing task is administered using Inquisit soft-
ware, based on Petrides and Milner (1982) from the
Inquisit test library [44]. Lastly, we administer an Inqui-
sit version of the Risky Gains Task developed by Paulus
et al. (2003) [45, 46]. Concerning discounting in adoles-
cents, studies have shown that individual differences in
decision-making are stable over time, as indicatated by
moderate to good test-retest reliability even over a 2-
year interval, with ICC-values ranging from 0.65 to 0.78
[47]. Lastly, we collect a scalp hair sample of (if possible)
at least 3 cm and analyze hair cortisol and testosterone
to obtain a biological measure of chronic stress. Hair
cortisol analysis is increasingly used in mental health re-
search, and is a reliable method to determine cortisol
levels over a prolonged period of time [48, 49]. In
addition, it has recently been shown that psychosocial
stress increases testosterone levels in both healthy con-
trols and patients with posttraumatic stress-disorder and
borderline personality disorder [50]. We therefore also
assess hair testosterone levels, in order to have an add-
itional read-out for physiological effects of chronic stress
and explore a potential link between elevated testoster-
one and impulse regulation issues among youth with
substance use disorders.
The end-of-treatment assessment will be limited to
documenting the judgement of the youth’s primary clin-
ician about the youth’s short-term treatment response
(partial or full remission; persistence; deterioration of
problematic substance use) and documenting the treat-
ment received (type; intensity; duration) and type of
treatment termination (premature; planned).
With the exception of most demographic background
variables and questions pertaining to pre-baseline his-
tory, the two- and four-year follow-up interviews will
focus on the same domains and include the same instru-
ments as the baseline assessment, with time-frames
adapted to the follow-up period. In addition, we will
inquire whether the youth experienced important ‘turn-
ing points’ or major life events that, in his or her view,
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had a major impact on the course of his/her substance
use in two- and four-years follow-up period.
Time to administer the baseline and follow-up assess-
ments is estimated at 2 and 1.5 h each, respectively. The
assessments will preferably be conducted at the treat-
ment center. Youth will receive a remuneration of 20, 30
and 50 euro for participating in the baseline and two-
and four-year follow-up, respectively. In addition, they
have the possibility to win a gift certificate of 200 euro
(6 certificates available) for follow-up attendance, as has
been done successfully in previous studies [51].
Power considerations
Using a sampling fraction of 10% to obtain a representa-
tive sample from the total target population (N = 4169;
see ‘Participants and setting’ above), we aim to include
420 youth in our study. Concerning our first study ques-
tion, we assume a 30% persistence rate of moderate to
severe SUD in our study sample [20, 21, 52]. With preci-
sion at 5% [53], a minimum sample size of N = 300
would be sufficient to estimate the assumed 30% persist-
ence rate with a 95% level of confidence [54].
However, for our prediction analyses of persistent
SUD (study questions 2, 3 and 5) we need a larger sam-
ple size than N = 300 to allow a sufficiently large number
of predictor variables to be included in the logistic re-
gression models. To avoid overfit of a logistic regression
model, authors recommend a minimum of 10 events
(i.e., 10 patients with persistent SUD) for each predictor
variable [55–57]. Hence, given the assumed 30% persist-
ence rate, and N = 420, a maximum of 12 predictor vari-
ables could be included in the multivariate logistic
regression analysis.
Data analysis
Study data will be analyzed following an intent-to-treat
(ITT) approach. The ITT-population consists of all pa-
tients who provide informed consent and receive at least
one treatment session.
(1) What is the persistence rate of DSM-5 moderate to
severe SUD from adolescence to young adulthood
among youth in the 2 and 4 years following entry in
addiction treatment?
Persistent moderate to severe SUD is defined as meet-
ing the criteria of lifetime moderate to severe SUD for
alcohol, cannabis, cocaine or amphetamines – collapsed
across substances – at baseline, as well as meeting the
criteria of past-year moderate to severe SUD at both the
2 year and 4 year follow-up. According to DSM-5, mod-
erate to severe SUD is defined as meeting four or more
of the 11 SUD-criteria. In case of missing follow-up data
we will conduct sensitivity analyses, using multiple
imputation methods based on post-baseline treatment,
end-of-treatment and follow-up data that we do have
available of a participant. We will also conduct a ‘worst-
case’ scenario analysis, in which those not reached at
both the two- and four-year follow-up are considered as
youth with persistent SUD. Notably, for youth without
past-year SUD at the 2 year follow-up and a missing 4
year follow-up (and vice versa), our primary outcome
variable is available: they are – by definition – youth
with non-persistent SUD.
(2) What is the prognostic value of a general
population-based set of predictors of persistent
SUD from adolescence to young adulthood for pre-
dicting persistent DSM-5 moderate to severe SUD
among youth in addiction treatment?
We will use existing data from the Tracking Adoles-
cents’ Individual Lives Survey (TRAILS) study to investi-
gate the rate of persistent substance dependence (DSM-
IV) and its predictors from adolescence to young adult-
hood in the general population. TRAILS is a prospective
cohort study (N = 2230) into the development of mental
health from preadolescence (age 11 years) to adulthood
(up to age 26 years) in the Dutch general population
with five biennial or triennial follow-up waves [58].
Candidate-predictors stem from the areas of: demo-
graphic background; substance use and SUD; non-SUD
mental disorders; family history; life events; and social
functioning (see first six domains in Table 1). Logistic
regression will be used to investigate the relation of
these predictors with the outcome variable, persistent
substance dependence, following the two-step procedure
suggested by Hosmer and Lemeshow (2000) [59]. Only
variables which are significantly associated with the out-
come variable in the first, univariate, step will be entered
as candidates into the multivariate (backward) logistic
regression model in the second step. Next, we will evalu-
ate the accuracy of the set of combined adolescent risk
factors found to predict persistent substance dependence
in the TRAILS cohort for predicting persistent DSM-5
moderate to severe SUD among youth in addiction treat-
ment, in terms of sensitivity, specificity, and positive and
negative predictive value.
(3) Can we optimize the accuracy of predicting
persistent DSM-5 moderate to severe SUD among
youth in addiction treatment by extending or modi-
fying the general population-based set of predictors
with baseline indicators from our addiction treat-
ment sample?
This question will be addressed (a) by building a new
prediction model based upon the same potential
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predictor variables as used in the TRAILS analysis above,
and supplement these with potential predictor variables
assessed at baseline in our addiction treatment sample
(Table 1), and (b) by comparing the accuracy of this
treatment-based prediction model with the TRAILS-
population-based prediction model.
(4) Which longitudinal treatment outcome trajectories
can be identified from adolescence to young
adulthood pertaining to substance use and SUD,
comorbid mental health problems, and social
functioning among youth in addiction treatment?
Concerning the fourth study question, we will use the
total count of DSM-5 SUD-symptoms derived from the
MATE-Y, and the sum score on the DASS-21 (mental
health problems) and WHODAS 2.0 (social functioning),
assessed at baseline and at two- and four-years follow-
up (Table 1). To describe the longitudinal course of
SUD, mental health problems and social functioning we
will employ latent growth curve modeling [60].
(5) Which treatment interventions – in terms of type,
intensity and duration – are associated with
favorable or unfavorable long-term outcomes, in
terms of substance use and SUD, mental health
problems and social functioning, for which youth in
addiction treatment?
The fifth study question will be answered in two suc-
cessive steps. First, we will determine which treatment
interventions are associated with a favorable treatment
outcome, using the same two-step logistic regression
procedure as described for study question 3. Next, we
will determine whether the youth-related potential pre-
dictors for persistent SUD (see study question 3) moder-
ate the favorable or unfavorable long-term outcomes of
the different treatment interventions. To determine
which treatment interventions are associated with a fa-
vorable long-term – two- and four-years – outcome, we
will categorize the treatment received along the follow-
ing dimensions: type of treatment; intensity; duration;
type of termination (see section ‘Treatment’ above).
All study questions will be analyzed using the statis-
tical software packages of SPSS version 25, R, and
Mplus, where appropriate.
Discussion
This study aims to investigate the long-term course of
SUD, concurrent mental health problems and social
functioning in a group that is particularly at risk for
chronicity: youth in addiction treatment. Strengths of
the study are (1) obtaining a nationally representative
sample of youth in addiction treatment, (2) the relatively
large size of our cohort, (3) the use of both self-report
and endophenotypical biological and cognitive-
behavioral data, and (4) our aim to determine the long-
term outcome of youth addiction treatment in a natural-
istic, ‘real world’ treatment context. Study limitations in-
clude the following. First, our study sample consists of
youth aged 16 to 22 years. We would have preferred to
include younger adolescents as well, but Dutch national
registration data showed that only 618 youths aged 15
years and younger seek help at addiction treatment an-
nually (i.e., 11% of total youths’ treatment demand). Sec-
ond, our maximum follow-up period is 4 years. We
would have preferred a longer follow-up period (e.g., 8
to 10 years) to sufficiently cover the age of young adult-
hood, but this was not possible due to budget limita-
tions. Third, our study data are in essence correlational
in nature, and hence, are subject to confounding. Includ-
ing a non-treatment control group would limit con-
founding, but for reasons of feasibility, ethics and costs,
we chose not to include a non-treatment (matched) con-
trol cohort in our study. Another option would have
been to conduct a large-scale randomized controlled
trial (RCT), but for obvious reasons an RCT with a non-
treatment control group would be unacceptable for eth-
ical reasons. Nevertheless, we will include important and
well-known confounders like social economic status in
our analyses. Lastly, most of our data are based on self-
report and may be subject to underreporting. Self-
reported substance use can be verified by means of urin-
alyses, but this method only provides a momentary as-
sessment and does not give an indication of amount or
severity of use. Studies indicate that self-report is quite
reliable if confidentiality is guaranteed and if no negative
consequences are attached to the answers provided by
the person [61, 62]. To assure that this will be the case,
our study assessments will be conducted by research-
assistants that are independent from treatment-staff.
Nevertheless, youths with insufficient comprehension of
basic Dutch language will be barred from the study (ex-
clusion criterion), and hence this potentially important
subpopulation will not be represented in our study data.
All in all, we are confident that this study will further
our understanding of (1) the course of SUD in youths
seeking help for their addiction problems, (2) the rela-
tionship between SUD and comorbid mental disorders
and social functioning over time, and (3) the determi-
nants and consequences of persistent SUD during the
transition from adolescence to young adulthood.
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